Bristol-Myers Squibb and Syngene International Extend Research

Bangalore, Karnataka, India and N.J., Princeton, United States- Business Wire
India 
Bristol-Myers Squibb (NYSE: BMY) and Syngene International, India's largest
contract research organization, today announced a five-year extension of their
drug discovery and development collaboration in India. Financial terms were not
disclosed. 
Since 2007, Bristol-Myers Squibb has been working with Syngene and its corporate
parent, Biocon Ltd., to develop integrated capabilities in medicinal and process
chemistry, biology, biotechnology, biomarkers, drug metabolism and
pharmacokinetics, analytical research, and pharmaceutical development at the
Biocon Bristol-Myers Squibb Research Center (BBRC) in Bangalore.     
The U.S.-India collaboration has produced six drug candidates for further study
and also helped Bristol-Myers Squibb reduce the time and costs associated with
advancing new compounds to first-in-human studies. One drug candidate currently
in clinical trials was discovered at BBRC and early nonclinical development work
done at BBRC has enabled most of Bristol-Myers Squibb's small molecule assets to
advance to later stages of development over the last five years. 
Commenting on the new agreement, Peter Bains, Director, Syngene International,
said: “We are extremely delighted to extend our discovery and development
partnership with Bristol-Myers Squibb for another five years. This extension
reflects the strength of our existing collaboration which has delivered many
successful outcomes. The scope of Syngene's engagement has expanded to encompass
a broad range of integrated service offerings across the drug discovery and
development continuum. We remain committed to supporting Bristol-Myers Squibb in
their pursuit of developing new and innovative medicines for the future.” 
Francis Cuss, Executive Vice President and Chief Scientific Officer,
Bristol-Myers Squibb, said: “I am excited about the opportunity to continue
our highly productive collaboration with Biocon and Syngene. The BBRC has
supported the nonclinical development of a large proportion of our
small-molecule portfolio assets since its inception, and is a premier example of
the high-quality innovative drug hunting that is taking place in India today.” 
Bristol-Myers Squibb and Syngene jointly developed the BBRC at Biocon Park in
Bangalore. Over the years, BBRC has become Bristol-Myers Squibb's largest
research and development center outside the United States, housing more than 400
scientists. 
About Bristol-Myers Squibb 
Bristol-Myers Squibb is a global specialty biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines that help
patients prevail over serious diseases. For more information, please visit
www.bms.com or follow us on Twitter at http://twitter.com/bmsnews/ 
Bristol-Myers Squibb Forward-Looking Statement 
This press release contains “forward-looking statements” as that term is
defined in the Private Securities Litigation Reform Act of 1995 regarding the
research, development and commercialization of pharmaceutical products. Such
forward-looking statements are based on current expectations and involve
inherent risks and uncertainties, including factors that could delay, divert or
change any of them, and could cause actual outcomes and results to differ
materially from current expectations. No forward-looking statement can be
guaranteed. Among other risks, there can be no guarantee that the compounds
mentioned in this release will move into full product development, that the
clinical trials of these compounds will support regulatory filings, that these
compounds will receive regulatory approval or, if approved, that they will
become commercially successful products. Forward-looking statements in this
press release should be evaluated together with the many uncertainties that
affect Bristol-Myers Squibb's business, particularly those identified in the
cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form
10-K for the year ended December 31, 2013, in our Quarterly Reports on Form 10-Q
and our Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no
obligation to publicly update any forward-looking statement, whether as a result
of new information, future events or otherwise. 
About Syngene International 
Syngene, a subsidiary of Biocon Ltd, is India's leading contract research
organization offering integrated drug discovery and development services with
capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology,
custom synthesis, process Research and Development, and formulation development
for small and large molecules. Syngene has an expert team of over 2,300
scientists and 1 million sq. ft. of built-up laboratories equipped with
state-of-the-art infrastructure to support the Research and Development programs
of global pharma, biotech and nutrition companies. More information is available
at www.syngeneintl.com. 
For more information please contact: 
Biocon & Syngene
Media: 
Seema Ahuja
Head-Corporate Communications
+919972317792
Email: seema.ahuja@biocon.com 
Rumman Ahmed
Manager-Corporate Communications
+919845104173
Email: rumman.ahmed@biocon.com 
Investors Contact  
Saurabh Paliwal
Head Investor Relations
+91 95383 80801
saurabh.paliwal@biocon.com 
Sweta Pachlangiya
Deputy Manager-Investor Relations
+91 96865 09372  sweta.pachlangiya@syngeneintl.com 
Bristol-Myers Squibb
Media: 
Frederick J. Egenolf
T: 609-252-4875
Email: frederick.egenolf@bms.com 
Investors  
Ranya Dajani 
T: 609-252-5330
Email: ranya.dajani@bms.com 
Ryan Asay
T:609-252-5020
Email: ryan.asay@bms.com 
Contributed via: Bloomberg Publisher WEB Service 
Provider ID: 1b11df72b53247959dcd064d12c98d55 
-0- Jun/03/2014 12:44 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.